Laryngeal cancer is the second most common respiratory tract malignancy, and the majority of laryngeal cancer (85%-95%) is laryngeal squamous cell carcinoma (LSCC). The incidence of LSCC has been increasing each year. In 2016, an estimated 13 430 new cases of laryngeal cancer were diagnosed, and ~3620 patients died from the disease.
endogenous RNAs or microRNA sponges in regulating alternative splicing or transcription mechanisms, and are thought to be involved in gene regulation during various biological processes and diseases. 5, 6 Cerebellar degeneration-related protein 1 antisense RNA (CDR1as), also known as circular RNA sponge for miR-7 (ciRS-7), was reported to antagonize miR-7 availability. 7 In islet cells, overexpression of CDR1as significantly increased both insulin content and secretion via miR-7/Myrip/Pax6 signals. 7 CDR1as-deficient brains of animals displayed impaired sensorimotor gating, which manifests in psychiatric disorders as a deficiency in the ability to filter out unnecessary information, and is associated with miR-7 and miR-671. 8 Moreover, CDR1as was found to be upregulated in gastric cancer, 9 colorectal cancer, 10 and hepatocellular carcinoma 11 tissues, and be predictive of a poor clinical outcome for cancer patients. However, the clinical role played by CDR1as in LSCC is unclear.
The availability of miR-7, a tumour suppressor, is reduced by
CDR1as during carcinogenesis by its targeting of EGFR/RAF1/
MAPK signals or the PTEN/PI3K/AKT signalling pathway.
6,12
Interestingly, a detailed genomic analysis from the Cancer Genome
Atlas Research Program (TCGA) indicated that these pathways have multiple potential therapeutic targets for laryngeal cancer, and these targets include EGFR, ERBB2, CCND1, TP53, and PIK3CD. 13 Thus,
we speculated that CDR1as/miR-7 signalling might be a promising therapy target for LSCC. In this study, we estimated the levels of CDR1as and miR-7 expression in LSCC samples, and determined its clinical significance. The functions of CDR1as and miR-7 were also investigated in vitro and in vivo. shRNA-CDR1as were synthesized by GenePharma (Shanghai, China).
| MATERIAL AND ME THODS

| Tumour samples, cell lines, and reagents
MiR-7 mimics and negative controls were purchased from RiboBio (Guangzhou, China). Anti-GAPDH, E-cadherin, N-cadherin, vimentin, CCNE1, and PIK3CD antibodies were obtained from Cell Signalling
Tech (Danvers, MA) and Abcam (Cambridge, MA).
| Cell transfection
Hep2 and AMC-HN-8 cells were seeded into 12 plates. Next, Lipofectamine 2000 (Invitrogen, Waltham, MA) was used to transfect the cells with Vector-CDR1as, shRNA-CDR1as, miR-7 mimics or a negative control for the indicated time period at a concentration of 1 ng/mL as described in the manufacturer's instructions.
| CCK-8 assay
Hep2 and AMC-HN-8 cells that had been transfected with VectorCDR1as, shRNA-CDR1as, miR-7 mimics or a negative control were harvested and washed with PBS. Regents contained in a Cell
Counting Kit-8 (Kumamoto, Japan) were mixed with DMEM and used for the cell viability assays. Absorbance was measured at 450 nm with a microplate reader.
| Colony formation assay
Hep2 and AMC-HN-8 cells overexpressing CDR1as and/or miR-7
were harvested and re-suspended in complete medium containing 10% FBS; after which, they were seeded into 12-well plates and cultured for 10 days. The cells were then stained with 0.1% crystal violet, fixed with methanol for 15 minutes, and visualized under a dissection microscope (Olympus, Tokyo, Japan). Colonies containing ≥50 cells or were counted.
| Flow cytometry assays
Hep2 and AMC-HN-8 cells used for cell cycle analysis were stained with PI staining solution (10 µg/mL RNase A and 50 µg/mL PL) at 
| Transwell assay
| Immunohistochemistry and immunofluorescence assays
Immunohistochemistry and immunofluorescence assays were performed as previously described. 14 Immunohistochemistry (IHC) was performed to determine the Ki-67 scores of the tumour tissues in the different groups.
| Xenograft animal studies
To examine the role played by CDR1as in vivo, Hep2 cells were transfected with lentivirus vector for miR-7, Vector-CDR1as, both miR-7
and vector-CDR1, or a negative control. Hep2 cells (2 × 10 
| Statistical analyses
All data were analysed using SPSS All experiments were performed at least three times.
| RE SULTS
| CDR1as predicted a poor clinical outcome in LSCC
To investigate the clinical significance of CDR1as in LSCC, the levels of CDR1as expression were assessed in the LSCC tissues (n = 30) and cor- Figure 1G ). Furthermore, we found that tumour suppressor miR-7 was downregulated in the tumour tissues ( Figure 1H ). An analysis of the correlation between CDR1as and tumour suppressor miR-7 showed that CDR1as levels were negatively associated with miR-7 levels in the LSCC samples ( Figure 1I ). These data indicated that upregulated CDR1as levels were associated with the progression of LSCC.
| CDR1as promoted the growth and metastasis of tumour cells in vitro
Because CDR1as predicts a poor clinical outcome for LSCC patients, Figure 2D ).
The cycle assays showed that knockdown of CDR1as induced G1/S phase arrest and apoptosis in both cell lines ( Figure 2E ,F, respectively).
We also examined the migration and invasion abilities of the
Hep2 and AMC-HN-8 cells. Overexpression of CDR1as enhanced
the migration and invasion abilities of the cells when compared to cells transfected with a negative control vector. However, inhibition of CDR1as produced the opposite effects ( Figure 2G ). The EMT phenotype was also induced by CDR1as, and this induction was accompanied by a decreased level of E-cadherin and increased levels of N-cadherin and vimentin ( Figure 2H,I ).
F I G U R E 1 Expression of CDR1as and miR-7 in LSCC.
A, The mRNA levels for CDR1as in samples of LSCC and relatively normal were determined by Q-PCR. B-F, The clinicopathological characteristics tumour-node-metastasis (TNM) stage (B), tumour differentiation (C), lymph node metastasis (D) gender (E) and age (F) of LSCC patients were analysed based on the expression of CDR1as. G, The correlation between survival time and the CDR1as expression were analysed in LSCC patients. H, The levels of mRNA for miR-7 in samples of LSCC tissue and relatively normal tissue were determined by Q-PCR. I, The correlation between CDR1as and miR-7 in LSCC was analysed. *P < 0.05, **P < 0.01, ***P < 0.001. Data represent the mean ± SD
| Mir-7 signals impaired the tumourigenic function of CDR1as in vitro
Our studies showed that CDR1as upregulates the miR-7 targets for LSCC growth and migration in vitro. To confirm the role of miR-7 in CDR1as-induced carcinogenesis, we forced overexpression of miR-7 in LSCC cells. When compared with cells that overexpressed CDR1as alone, cells that co-expressed CDR1as and miR-7 displayed decreased proliferation, impaired vitality ( Figure 3A,B) , reduced rates of colony formation ( Figure 3C ), G1/S arrest, increased rates of apoptosis ( Figure 3D ,E), and reduced migration and invasion capabilities ( Figure 3F ). In addition, the CDR1as-induced EMT phenotype of the LSCC cells was reversed by miR-7 ( Figure 3G ,H). These data indicated that restoration of miR-7 expression in LSCC cells could inhibit the tumourigenic function of CDR1as. 
| The targets of mir-7 were upregulated by CDR1as
Because miR-7 and its targets appeared to be regulated by CDR1as
for tumour progression, we estimated the impacts of CDR1as on the miR-7 targets in LSCC cells. We found that CDR1as increased the levels of CCNE1 and PIK3CD mRNA and proteins in Hep2 ( Figure 4A,B) and AMC-HN-8 ( Figure 4C ,D) cells, which was conducive to tumour proliferation and metastasis. Moreover, we also confirmed that although the miR-7 target genes CCNE1 and PIK3CD could be induced by CDR1as, restoration of tumour suppressor miR-7 expression abrogated this process and inhibited the expression of CCNE1
and PIK3CD in the two cell lines. This indicated the involvement of miR-7/CCNE1/PIK3CD in CDR1as-induced LSCC tumour growth.
| The tumourigenic role of CDR1as in vivo
We next examined the tumourigenic role of CDR1as in vivo. Nude mice were implanted with human Hep2 cells that overexpressed miR-7, CDR1as or both. The results indicated that overexpression of CDR1as alone significantly promoted tumour growth and increased tumour volume, whereas the mice implanted with Hep2 cells that highly expressed both miR-7 and CDR1as had smaller tumours ( Figure 5A ,B). Tumour proliferation was confirmed by the index Ki-67 level in the tumour ( Figure 5C ). The EMT phenotype and levels of CCNE1 and PIK3CD expression were determined and showed that CDR1as could promote the EMT and increase cellular CCNE1
and PIK3CD levels in vivo; both of these processes were inhibited by miR-7 ( Figure 5D-F) . These results demonstrated that CDR1as participated into the progression of LSCC via miR-7 signals.
| D ISCUSS I ON
As the second most common cancer in the head and neck region, the overall survival time of LSCC patients, and especially advancedstage patients, has not significantly improved during the past several decades. 1 In this study, we sought to discover new therapeutic targets for LSCC. CircRNAs play important roles in the initiation and development of cancers, and mainly serve as microRNA sponges that regulate gene expression. 15 CDR1as is one of the few circRNAs that has been proposed to inhibit tumour suppressor miR-7. We found that CDR1as functions as an oncogene and is upregulated in LSCC tissue to promote tumour progression via miR-7 both in vitro and in vivo.
Unlike linear RNA molecules, the 3′ and 5′ ends of circRNAs are joined together by covalent bonds, leading to circularization. This prevents the degradation of circRNA by RNA exonucleases. 16 It also increases the structural stability of circRNAs and makes them very abundant in the cytoplasm. Given their conservation, abundance, and tissue specificity, circRNAs may play roles as special molecular markers in cancer. 17 In this study, we found that the levels of F I G U R E 5 CDR1as regulated miR-7 activity to promote tumour growth in vivo. Hep-2 cells containing the lentivirus vector for vectorCDR1as or miR-7 alone, or both were subcutaneously injected into nude mice. A-B, The growth rates and average weights of the tumours in the different treatment groups were estimated at the time the animals were sacrificed. C, The levels of Ki67 expression in the tumour tissues in the different groups were estimated by IHC. D-F, The EMT phenotype (N-cadherin, E-cadherin, CCNE1, and PIK3CD levels) was determined by Q-PCR, WB and IHC assays. **P < 0.01, ***P < 0.001, data represent the mean ± SD hsa_circRNA_104912 expression. 18 Similarly, other circRNAs have also been proposed as cancer biomarkers. expression. 23 In colorectal cancer (CRC), inhibition of CDR1as suppressed CRC cell proliferation and invasion, and a miR-7 inhibitor was able to rescue the function of CDR1as knockdown.
This rescue might attributed to tumour growth and the invasionrelated miR-7 targets, EGFR and IGF-1R. 9 Another study showed that EGFR-RAF1 activity was regulated by CDR1as/miR-7 signals in CRC patients. Furthermore, the results of in vivo studies showed that CDR1as impaired the tumour-induced suppression of miR-7 and thereby promoted tumour growth in CRC. 19 In this study, we confirmed the tumourigenic role of CDR1as in vivo.
Interestingly, we found that overexpressed CDR1as alone could accelerate the growth of LSCC tumours, and this effect helped to counteract the function of miR-7 by promoting tumour growth and upregulating the invasion-related miR-7 targets, CCNE1 and PIK3CD, in tumour cells.
| CON CLUS ION
In conclusion, we reported the presence of oncogene CDR1as in LSCC cells. High levels of CDR1as promoted LSCC growth and metastasis via regulation of the miR-7/CCNE1/PIK3CD signalling pathway. High levels of CDR1as were predictive of a poor clinical outcome and might serve as a novel biomarker for LSCC patients.
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